<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1018">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370782</url>
  </required_header>
  <id_info>
    <org_study_id>20-21</org_study_id>
    <nct_id>NCT04370782</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting</brief_title>
  <official_title>A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Francis Hospital, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Francis Hospital, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label trial to assess the safety and efficacy of
      hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a
      higher risk COVID-19 positive outpatient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID-19 is an aggressive and contagious virus, found to have high mortality especially in
      persons with comorbidities (Age&gt;60, hypertension [HTN], diabetes mellitus [DM], Cancer, and
      otherwise immunocompromised). Zinc is a supplement with possible antiviral properties, having
      been shown to have effect in the common cold, many of which are due to coronavirus. In
      addition, elderly patients and patients with co-morbidities have high incidence of zinc
      deficiency. We are repleting zinc in all patients and studying its direct effect in
      combination with hydroxychloroquine, and an antibiotic, either azithromycin or doxycycline to
      see if there is enhanced treatment efficacy in early COVID-19 infection and assess the safety
      of these two regimen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Resolution of Symptoms relative to baseline (day 1 of trial)</measure>
    <time_frame>Day 5</time_frame>
    <description>Patients will be assessed on day 5 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Resolution of Symptoms relative to baseline (day 1 of trial)</measure>
    <time_frame>Day 14</time_frame>
    <description>Patients will be assessed on day 14 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Resolution of Symptoms relative to baseline (day 1 of trial)</measure>
    <time_frame>Day 21</time_frame>
    <description>Patients will be assessed on day 21 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants hospitalized and/or requiring repeat ER visits</measure>
    <time_frame>21 days</time_frame>
    <description>Number of participants hospitalized and/or requiring repeat ER visits related to COVID-19 complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>Until Discharged up to 30 days</time_frame>
    <description>If hospitalized, number of participants admitted to the ICU, and number of days in the ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilator</measure>
    <time_frame>Until extubated up to 30 days</time_frame>
    <description>If placed on ventilator, number of days on a ventilator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of symptoms</measure>
    <time_frame>Day 5, Day 14, and Day 21</time_frame>
    <description>Severity of symptoms evaluated at day 5, day 14, and day 21 scored by the participant for feverishness, sore throat, cough, shortness of breath, myalgias. (0 =none; 1 = mild; 2 = moderate; 3 = severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events due to drug regimen</measure>
    <time_frame>21 days</time_frame>
    <description>Number of participants with adverse events due to drug regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with QTc prolongation &gt;500ms</measure>
    <time_frame>Days 1 thru 5, Day 10, Day 21</time_frame>
    <description>Assess all patients to evaluate for QTc prolongation &gt;500ms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine
Azithromycin
Zinc sulfate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxychloroquine
Doxycycline
Zinc sulfate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine 400mg twice a day (BID) on day 1, followed by 200mg BID for days 2-5</description>
    <arm_group_label>Experimental Arm 1</arm_group_label>
    <arm_group_label>Experimental Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin 500mg on day 1, followed by 250mg once daily for days 2-5</description>
    <arm_group_label>Experimental Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc Sulfate</intervention_name>
    <description>Zinc sulfate 220mg once daily for 5 days</description>
    <arm_group_label>Experimental Arm 1</arm_group_label>
    <arm_group_label>Experimental Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline 200 mg once daily for 5 days</description>
    <arm_group_label>Experimental Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to read and understand informed consent.

          -  High initial clinical suspicion by physician based on signs and symptoms (fever,
             cough, myalgias, fatigue, shortness of breath) followed by RT-PCR for confirmation of
             COVID-19 diagnosis

          -  Any gender

          -  Age 60 years and older

          -  Age 30-59 years with one or more of the following:

               -  abnormal lung exam

               -  abnormal oxygen staturation &lt;95%

               -  abnormal chest x-ray or chest CT

               -  persistent fever &gt;100.4 degrees Fahrenheit upon arrival to Emergency department
                  (ED)

               -  one of the following co-morbidities: hypertension, diabetes mellitus, history of
                  coronary artery disease, chronic kidney disease (CKD), asthma, chronic
                  obstructive pulmonary disease, current or former smoker, or morbid obesity (Body
                  Mass Index ≥35)

        Exclusion Criteria:

          -  Pregnant or breastfeeding female

          -  Severe COVID-19 requiring admission for inpatient treatment

          -  Need for any oxygen supplementation

          -  Need for mechanical ventilatory support

          -  History of oxygen supplementation dependency

          -  History of cancer with ongoing chemotherapy or radiation therapy

          -  Concurrent antimicrobial therapy

          -  Known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds

          -  Already taking hydroxychloroquine or chloroquine within 1 month

          -  Known G6-PD deficiency

          -  History of retinopathy

          -  History of current cardiac diseases (heart failure, ventricular arrhythmias, Left
             bundle branch block and/or Right bundle branch block, QTc prolongation &gt;480ms), or
             family history of sudden cardiac death

          -  Ongoing use of drugs that prolong the QTc interval (antipsychotics, antidepressants,
             class I and III antiarrhythmics, triptans)

          -  Severe renal disease: glomerular filtration rate (GFR) &lt;30ml/min

          -  Severe hepatic impairment (elevated total bilirubin &gt;2 mg/dL, decreased albumin &lt;2.8
             g/dL, signs of jaundice and ascites.)

          -  Active alcohol abuse (&gt;5 drinks per day or &gt;20 drinks per week.)

          -  Seizure disorder, currently on medications

          -  Known hypersensitivity to any tetracyclines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avni Thakore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Francis Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avni Thakore, MD</last_name>
    <phone>516-563-7938</phone>
    <email>avni.thakore@chsli.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth S Haag, RN</last_name>
    <phone>516-622-4512</phone>
    <email>elizabeth.haag@chsli.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Haag, RN</last_name>
      <phone>516-622-4512</phone>
      <email>elizabeth.haag@chsli.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.</citation>
    <PMID>32020029</PMID>
  </reference>
  <reference>
    <citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.</citation>
    <PMID>32150618</PMID>
  </reference>
  <reference>
    <citation>Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.</citation>
    <PMID>32171740</PMID>
  </reference>
  <reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.</citation>
    <PMID>32205204</PMID>
  </reference>
  <reference>
    <citation>Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, Graef ER, Korsten P, Sattui SE, Sirotich E, Ugarte-Gil MF, Webb K, Grainger R. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Ann Intern Med. 2020 Jun 16;172(12):819-821. doi: 10.7326/M20-1223. Epub 2020 Mar 30. Erratum in: Ann Intern Med. 2020 Jun 16;172(12):844.</citation>
    <PMID>32227189</PMID>
  </reference>
  <reference>
    <citation>Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, Zheng M, Chen L, Li H. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020 May;10(5):766-788. doi: 10.1016/j.apsb.2020.02.008. Epub 2020 Feb 27.</citation>
    <PMID>32292689</PMID>
  </reference>
  <reference>
    <citation>Korant BD, Butterworth BE. Inhibition by zinc of rhinovirus protein cleavage: interaction of zinc with capsid polypeptides. J Virol. 1976 Apr;18(1):298-306.</citation>
    <PMID>176466</PMID>
  </reference>
  <reference>
    <citation>Katz E, Margalith E. Inhibition of vaccinia virus maturation by zinc chloride. Antimicrob Agents Chemother. 1981 Feb;19(2):213-7.</citation>
    <PMID>7347557</PMID>
  </reference>
  <reference>
    <citation>Kümel G, Schrader S, Zentgraf H, Daus H, Brendel M. The mechanism of the antiherpetic activity of zinc sulphate. J Gen Virol. 1990 Dec;71 ( Pt 12):2989-97.</citation>
    <PMID>2177090</PMID>
  </reference>
  <reference>
    <citation>Suara RO, Crowe JE Jr. Effect of zinc salts on respiratory syncytial virus replication. Antimicrob Agents Chemother. 2004 Mar;48(3):783-90.</citation>
    <PMID>14982765</PMID>
  </reference>
  <reference>
    <citation>Eby GA, Davis DR, Halcomb WW. Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother. 1984 Jan;25(1):20-4.</citation>
    <PMID>6367635</PMID>
  </reference>
  <reference>
    <citation>te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010 Nov 4;6(11):e1001176. doi: 10.1371/journal.ppat.1001176.</citation>
    <PMID>21079686</PMID>
  </reference>
  <reference>
    <citation>Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev. 2013 Jun 18;(6):CD001364. doi: 10.1002/14651858.CD001364.pub4. Review. Update in: Cochrane Database Syst Rev. 2015;(4):CD001364.</citation>
    <PMID>23775705</PMID>
  </reference>
  <reference>
    <citation>Bao S, Knoell DL. Zinc modulates airway epithelium susceptibility to death receptor-mediated apoptosis. Am J Physiol Lung Cell Mol Physiol. 2006 Mar;290(3):L433-41. Epub 2005 Nov 11.</citation>
    <PMID>16284213</PMID>
  </reference>
  <reference>
    <citation>Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding WQ. Chloroquine is a zinc ionophore. PLoS One. 2014 Oct 1;9(10):e109180. doi: 10.1371/journal.pone.0109180. eCollection 2014.</citation>
    <PMID>25271834</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Francis Hospital, New York</investigator_affiliation>
    <investigator_full_name>Avni Thakore MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>coronavirus</keyword>
  <keyword>hydroxychloroquine</keyword>
  <keyword>zinc sulfate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Zinc Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

